- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00998335
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes
The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty liver disease (NAFLD) has not been systematically studied before, and in particular, never when using the new insulin formulations detemir (Levemir®) or aspart (Novolog®). This study is to determine the effect on hepatic steatosis and insulin secretion/action of lowering the fasting plasma glucose (FPG) to target with once daily basal insulin detemir alone or combining insulin detemir with premeal insulin aspart in patients with uncontrolled type 2 diabetes mellitus (T2DM).
In the first 3 months the investigators will optimize metabolic control in all patients with intensive basal (bedtime) detemir insulin aiming at a normal fasting plasma glucose. After this treatment period, patients will be randomized in the second 3 months in a 2:1 ratio to insulin detemir or detemir plus aspart. The investigators propose that insulin will improve day-long glycemic control and A1c, reduce hepatic steatosis (NAFLD) (primary endpoint) and insulin secretion/sensitivity being well tolerated while causing minimal weight gain and hypoglycemia (secondary endpoints). The study will allow to assess if there is an additional benefit of adding pre-meal rapid-acting insulin aspart to basal insulin to these endpoints.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The control of hyperglycemia in T2DM ameliorates the metabolic abnormalities of T2DM but whether this improves hepatic steatosis has not been examined carefully with the use of improved insulin formulations (long-acting insulins detemir or glargine, alone or combined with pre-meal short-acting insulins). Most research studies have focused on glycemic control without a careful examination to the underlying mechanisms, with some of these studies reporting on improved hepatic and muscle insulin sensitivity. The investigators have found in the laboratory that intensified insulin therapy in T2DM is associated with enhanced glycogen synthase fractional velocity and non-oxidative glucose disposal, but with no improvement at the level of insulin-stimulated insulin receptor tyrosine phosphorylation, hexokinase II mRNA or enzyme function, phosphatidylinositol 3-kinase (PI 3-kinase) associated with IRS-1, or Akt phosphorylation. Our work did not examine hepatic steatosis or insulin secretion/action, nor was designed to distinguish between the relative contribution of reduced glucotoxicity on insulin sensitivity vs. beta-cell function from pre-meal regular vs. NPH insulin. It is possible that the beneficial effects of insulin therapy of reduced plasma glucose and FFA concentrations may be offset by excessive hyperinsulinemia and weight gain from the use of insulins with suboptimal pharmacokinetics compared to the newer insulin formulations.
Insulin detemir is an insulin analogue approved in 2005 by the FDA. It is a long-acting insulin analogue that has shown to be more predictable in achieving therapeutic plasma insulin levels compared to NPH insulin. This is associated with several clinical benefits, such as better glycemic control, less hypoglycemia, modest weight gain and better quality of life for patients with type 2 diabetes. If gluco-lipotoxicity likely play an important role in the development of hepatic steatosis (NAFLD) in T2DM the investigators speculate that if reversed by a strategy of basal long-acting insulin (insulin detemir) alone, or combined with a rapid-acting analog (pre-meal insulin aspart) may be a good strategy for the treatment of T2DM.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229-3900
- The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To participate patients must:
- Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent.
- Female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy are eligible for participation in the study. Female patients (except for those patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period.
- Age range of 18 to 70 years (inclusive).
- Patients must have been on a stable dose of allowed chronic medications for two months prior to entering the double-blind treatment period.
All participants must have the following laboratory values:
- Hemoglobin ≥ 12 g/dl in males or ≥ 11 g/dl in females
- Serum creatinine ≤ 1.5 mg/dl
- AST (SGOT) ≤ 2.5 times upper limit of normal
- ALT (SGPT) ≤ 2.5 times upper limit of normal
- Alkaline phosphatase ≤ 2.5 times upper limit of normal
Exclusion Criteria:
Patients will be excluded if any of the following criteria are present:
- Individuals with type 1 diabetes or type 2 diabetes and a FPG ≥ 300 mg/dl.
- Subjects on sulfonylureas, metformin and/or TZDs unless the dose has been stable for at least 2 months prior to study entry.
- Patients on any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on stable doses of such agents for the past two months before entry into the study. Patients may be taking stable doses of estrogens or other hormonal replacement therapy if the patient has been on these agents for the prior two months. Patients taking systemic glucocorticoids will be excluded.
- Past (within 1 year) or current history of alcohol abuse.
- Patients will be excluded if there is a history of clinically significant heart disease (New York Heart Classification greater than grade II), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) or chronic renal failure (serum creatinine greater than 1.5 mg/dl).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Insulin detemir only
Patients with uncontrolled T2DM are treated with insulin detemir for 6 months.
Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
This group will receive Long-acting bedtime insulin detemir (Levemir).
|
This group will receive Insulin detemir.
Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
Other Names:
|
Experimental: Insulin detemir plus aspart
After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl.
After 3 months patients will be admitted to assess the metabolic effects of intervention.
After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose.
After another 3 months patients are readmitted and all study procedures repeated.
This group will receive Insulin detemir and pre-meal insulin aspart.
|
This group will receive Insulin detemir plus aspart.
The group will start with Insulin detemir at bedtime.
Then in three months they will Insulin aspart before breakfast, lunch and dinner.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatic Steatosis
Time Frame: 3 and 6 months
|
Hepatic steatosis measured by proton magnetic resonance spectroscopy (1H-MRS).
|
3 and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic Control as Measured by the A1c
Time Frame: 3 and 6 months
|
3 and 6 months
|
|
Change in Insulin Secretion
Time Frame: 3 and 6 months.
|
Derived from the hyperglycemic clamp (Plasma C-peptide change vs. pretreatment in first and second phase).
|
3 and 6 months.
|
Intramyocellular (IMCL) by Magnetic Resonance Imaging and Spectroscopy (MRS).
Time Frame: 3 and 6 months.
|
Percent intramyocellular (IMCL) by magnetic resonance imaging and spectroscopy (MRS).
|
3 and 6 months.
|
Plasma Lipid Concentration.
Time Frame: 3 and 6 months.
|
Fasting plasma lipid concentration on day of admission at 3 and 6 months.
|
3 and 6 months.
|
Change in Anthropometric Measure (Body Weight).
Time Frame: 3 and 6 months.
|
Change in anthropometric measure (body weight) done on day of admission at 3 and 6 months.
|
3 and 6 months.
|
Number of Hypoglycemic Events
Time Frame: 3 and 6 months
|
Defined as hypoglycemia <40 mg/dl and/or requiring medical assistance during the trial.
|
3 and 6 months
|
Metabolic Control as Measured by the Fasting Plasma Glucose Concentration
Time Frame: 3 and 6 months
|
3 and 6 months
|
|
Metabolic Control as Measured by the Postprandial Plasma Glucose During the Day-long Plasma Glucose Profile.
Time Frame: 3 and 6 months
|
3 and 6 months
|
|
Advanced Lipid Testing
Time Frame: 3 and 6 months
|
Change in lipoprotein particle number was determined using NMR.
|
3 and 6 months
|
Change in Anthropometric Measure (Body Mass Index [BMI]).
Time Frame: 3 and 6 months.
|
Change in anthropometric measure (body mass index [BMI]) done on day of admission at 3 and 6 months.
|
3 and 6 months.
|
Percent Change From Baseline in Vascular Inflammatory Markers
Time Frame: 3 and 6 months
|
Inflammatory Markers include: Adiponectin, MMP-9, E-selectin, sICAM, and sVCAM
|
3 and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kenneth Cusi, M.D., University of Flordia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20060167
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Long-acting bedtime insulin detemir (Levemir)
-
Institut de Recherches Cliniques de MontrealNovo Nordisk A/S; McMaster UniversityCompleted
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Biologics & Biosimilars Collective Intelligence...Merck Sharp & Dohme LLC; Pfizer; AbbVie; University of Pittsburgh; Boehringer Ingelheim and other collaboratorsCompleted
-
Novo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | DiabetesIsrael, Italy, United Kingdom, Denmark, Spain, Singapore, Taiwan, Germany, France, Hong Kong, Brazil
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesAustria, Germany, Switzerland
-
Munich Municipal HospitalNovo Nordisk A/SUnknownType 2 Diabetes MellitusGermany
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1United States, Poland, Finland, Belgium, Hungary, United Kingdom, Germany, Canada, Czechia
-
Rabin Medical CenterCompletedType 1 Diabetes MellitusIsrael
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Indonesia
-
Emory UniversityCompleted